linjc16/ctgov huggingface dataset:
Supermicrosurgical Lymphvenous Bypass Intervention for Treatment

Study Overview
=================
Brief Summary
-----------------
Background: In addition to antegrade anastomosis, retrograde anastomosis has been thought to offer further improvements after lymphaticovenous anastomosis (LVA) by bypassing the retrograde lymphatic flow. However, this concept has yet to be validated. The aim of this study was to determine the impacts on outcomes of performing both retrograde and antegrade anastomosis, as compared to antegrade-only anastomosis for treating lower limb lymphedema.

Official Title
-----------------
Supermicrosurgical Lymphvenous Bypass Intervention for Lymphedema Treatment

Conditions
-----------------
Lymphedema of Leg

Intervention / Treatment
-----------------
* Other: Antegrade and retrograde anastomoses
* Other: Antegrade-only anastomoses


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Lower limb lymphedema patients. Exclusion Criteria: Patients who have had previous LVA, liposuction, or excisional therapy such as the Charles procedure were excluded.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Lower limb lymphedema patients<br>This was a retrospective cohort propensity score-matched study. Patients with lower limb lymphedema were enrolled. | Other: Antegrade and retrograde anastomoses<br>* Patients who had received both antegrade and retrograde anastomoses.<br>Other: Antegrade-only anastomoses<br>* Patients who had received antegrade-only anastomoses.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Magnetic resonance volumetry | Magnetic resonance volumetry was used for outcome assessments. The primary endpoint was the volume change at 6 months after LVA. | 6 months after LVA |
Levothyroxine for Children With Euthyroid Sick Syndrome

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether levothyroxine is effective and safe in the treatment of children with euthyroid sick syndrome, hospitalized in a pediatric intensive care unit.

Detailed Description
-----------------
Children with euthyroid sick syndrome, hospitalized in a pediatric intensive care unit, will be randomised to receive either Levothyroxine or placebo, to determine if it diminishes mortality.

Official Title
-----------------
Efficacy and Safety of Levothyroxine in Critical Children With Euthyroid Sick Syndrome in a Pediatric Intensive Care Unit.

Conditions
-----------------
Euthyroid Sick Syndrome

Intervention / Treatment
-----------------
* Drug: Levothyroxine
* Other: Calcium magnesia


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All children aged 1 month to 17 years. Admitted to pediatric intensive care unit. TSH and thyroid hormones below age specific levels. Exclusion Criteria: Known thyroid condition. Brain death. Gut conditions that contraindicate oral route. Readmissions to intensive care unit.

Ages Eligible for Study
-----------------
Minimum Age: 1 Month
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Levothyroxine<br>3 mcg/kg/day | Drug: Levothyroxine<br>* 3 mcg/kg/day<br>* Other names: Brand: Eutirox.;|
| Placebo Comparator: Control<br>Calcium magnesia. | Other: Calcium magnesia<br>* Placebo.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| All cause mortality |  | participants will be followed for the duration of hospital stay, an expected average of 3 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Length of time in intensive care |  | participants will be followed for the duration of hospital stay, an expected average of 2 weeks | 
| Ventilation days |  | participants will be followed for the duration of hospital stay, an expected average of 2 weeks | 
| Use of vasopressors |  | participants will be followed for the duration of hospital stay, an expected average of 3 weeks | 
| Thyroid hormones levels |  | participants will be followed for the duration of hospital stay, an expected average of 3 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Euthyroid Sick Syndromes, Intensive care, Thyroxine
Use of Music in Reducing Pain During Outpatient Hysteroscopy in Primarily Infertile Patients

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to demonstrate the value of music in outpatient hysteroscopy on patients' level of pain and satisfaction in primarily infertile patients.

Official Title
-----------------
Use of Music in Reducing Pain During Outpatient Hysteroscopy in Primarily Infertile Patients: Prospective Randomized Trial

Conditions
-----------------
Hysteroscopy

Intervention / Treatment
-----------------
* Other: music
* Other: no-music


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: women with primary infertility requiring a diagnostic hysteroscopy as a part of an infertility diagnosis workup Exclusion Criteria: women with suspected pregnancy heavy vaginal bleeding recent pelvic infection those who received analgesics prior to OH a concomitant neurologic disease that could affect the correct evaluation of pain
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: music group<br>In the music group, music chosen by the participant will be played through a speaker by the nursing staff during outpatient hysteroscopy. Music will be played through a speaker instead of headphones in order to maintain good communication and interaction between the participant and the doctor. | Other: music<br>* In the music group, music chosen by the participant will be played through a speaker by the nursing staff during outpatient hysteroscopy. Music will be played through a speaker instead of headphones in order to maintain good communication and interaction between the participant and the doctor.<br>|
| Other: non-music group<br>Participants in the non-music group will undergo outpatient hysteroscopy in the same setting and standard procedure without listening to any music. | Other: no-music<br>* Participants in the non-music group will undergo outpatient hysteroscopy in the same setting and standard procedure without listening to any music.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Intensity of pain | Pain intensity will be assessed by visual analogue scale during the procedure.visual analogue scale ranging from 0 to 10 | 5 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Intensity of pain | Pain intensity will be assessed by visual analogue scale 30 minutes after the procedure.visual analogue scale ranging from 0 to 10 | 30 minutes | 
| women satisfaction | satisfaction will be assessed by visual analogue scale-like scale ranging from 0 to 10 (0=no satisfaction; 10=maximal satisfaction) | 30 minutes |
OPsumit USers Registry

Study Overview
=================
Brief Summary
-----------------
Prospective observational drug registry developed to characterize the safety profile (including primarily potential serious hepatic risks) and to describe clinical characteristics and outcomes of patients newly treated with Opsumit in the post-marketing setting.

Official Title
-----------------
US-based, Observational, Drug Registry of Opsumit® (Macitentan) New Users in Clinical Practice

Conditions
-----------------
Pulmonary Arterial Hypertension

Intervention / Treatment
-----------------
* Drug: Opsumit (macitentan)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients newly treated with Opsumit defined as a new user of therapy, initiated ≤ 30 days prior to enrollment visit. Signed ICF Exclusion Criteria: Previous user of Opsumit defined as patient who initiated therapy >30 days prior to enrollment. Patients enrolled in any ongoing clinical trials
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Opsumit (macitentan)<br>10 mg tablets | Drug: Opsumit (macitentan)<br>* 10 mg tablets<br>* Other names: ACT-064992;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To estimate incidence rates for specified outcomes. | Liver test abnormalities/ Occurrence of Hepatic Adverse Events (HAEs)/ Occurrence of any other AEs/ Discontinuation of Opsumit and reason for stopping therapy/ Hospitalization and death. | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To describe demographic and clinical characteristics of patients treated with Opsumit at enrollment and during observation period. |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PAH, pulmonary arterial hypertension
Bimetric-10: Investigation of Patients Who Have Underwent Total Hip Arthroplasty With a Cemented Bi-Metric Stem

Study Overview
=================
Brief Summary
-----------------
This is a 10 year follow-up investigation of patients who have underwent total hip arthroplasty with a cemented Bimetric stem.

Official Title
-----------------
10 Year Follow-up Investigation of Patients Who Have Underwent Total Hip Arthroplasty With a Cemented Bi-metric Stem

Conditions
-----------------
Osteoarthrosis

Intervention / Treatment
-----------------
* Device: Bimetric femoral stem


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Osteoarthrosis Exclusion criteria: Malignancies

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1: Cemented Bi-Metric femoral stem<br>Cemented Bi-Metric femoral stem | Device: Bimetric femoral stem<br>* Cemented Bi-Metric femoral stem<br>* Other names: Cemented Bi-Metric femoral stem;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Osteoarthritis
Correlating the Measure of Retinal Vascular Density Through Angio-OCT With Calcium Score

Study Overview
=================
Brief Summary
-----------------
Recent case-control studies have proven that the retinal vascularization mirrors the cardiac vascularization: more the coronary network is altered, more the density of retinal vessels is reduced. No studies have yet been realised in primary prevention. This study aims to demonstrate a link between the density of the retinal vascularization and the calcium score, which is currently the gold standard for the classification of cardiovascular risk in primary prevention. Thus, a simple image of the retinal vascularization could predict the cardiovascular risk of a patient. OCT angiography would become a major aid in the classification of cardiovascular risk in asymptomatic patients.

Official Title
-----------------
Correlating the Measure of Retinal Vascular Density Through Angio-OCT With Calcium Score

Conditions
-----------------
Cardiovascular Abnormalities, Vascular Diseases, Retinal Vascular

Intervention / Treatment
-----------------
* Other: Ophthalmologic consultation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients eligible for a calcium score as part of their standard treatment and volunteers for an ophthalmologic consultation Exclusion Criteria: Pregnant women

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: ophthalmology consultation<br>Patients eligible to calcium score will be offered an ophthalmologic consultation including Angio-Optical Coherence Tomography [OCT] | Other: Ophthalmologic consultation<br>* Complete ophthalmologic examination including angio-OCT<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation between retinal vascular density and calcium score | Comparison between values of calcium score and presence of vascular abnormalities in retina. Calcium is scored as follows: Coronary Artery Calcium [CAC] = 0 : very low risk CAC = [1-100[ : low risk CAC = [100-400[ : moderate risque CAC = [400-1000[ : high risk CAC = > 1000 : very high risk | Day 1 |
The Prevalence and Clinical Manifestations of Human Metapneumovirus Among Children With Bronchiolitis.

Study Overview
=================
Brief Summary
-----------------
Sputum specimens will be obtained from children < 2 years of age and processed by different mode for the HMPV, RSV, Pertussis, Influenza A, B, Parainfluenza 1,2,3, Adenovirus. Clinical and epidemiological data will also be obtained.

Detailed Description
-----------------
The purpose of the study is to asses the various pathogens of bronchiolitis in children and its' clinical manifestations. Prospective study in 3 Medical centers in Northern Israel. Included will be about 200 infants and children < 2 years hospitalized with bronchiolitis. From each child sputum specimen will be obtained and processed for HUMP - PCR, Pertussis - PCR, RSV - ELISA, DFA, PCR, Influenza A, B, Parainfluenza 1,2,3 - DFA, PCR, Adenovirus - DFA. Epidemiological data will be obtained for every child by structured questioner. Clinical data will be daily obtained by scoring system.

Official Title
-----------------
The Prevalence and Clinical Manifestations of Human Metapneumovirus Among Children With Bronchiolitis in Northern Israel.

Conditions
-----------------
Respiratory Tract Infection, Children

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria:Age 0-24 months, hospitalized children, - Exclusion Criteria:Previous hospitalization, previous RSV immunization, immunocompromised patient, previous inclusion in this study, inclusion in another study. -

Ages Eligible for Study
-----------------
Minimum Age: 1 Day
Maximum Age: 2 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
child, bronchiolitis,
Evaluation of Outcomes From Treatment of Benign or Malignant Pancreatic Diseases

Study Overview
=================
Brief Summary
-----------------
This study will be a retrospective chart review of patients who have been diagnosed with the benign or malignant pancreatic disease under the practice of Dr. Rohan Jeyarajah, M.D., Dr. Houssam Osman M.D., and Dr. Edward Cho M.D., Sc.M. at Methodist Health System Hospital in Richardson, TX. The investigators plan to conduct an analysis of patients meeting the inclusion criteria from 2005 to present. Study will also be conducted by the PI, Sub-Is, surgery fellows, office staff and clinical research coordinator who are delegated to do by the PI. Data will be obtained by looking through either investigator's patients or through a national database. Data will be analyzed primarily by the study conductors.

Detailed Description
-----------------
It is reported in the literature that the treatment of any pancreatic disease process, whether benign or malignant, continues to be a huge challenge. For example, patients with adenocarcinoma continue to be diagnosed at an advanced stage with medical and surgical options that are improving in terms of outcome measurements but with much more room for improvement. The investigator's goal is to continue to review our treatment outcomes to further improve overall survival, overall symptom control, mortality, and morbidity. The main aim of this study is to evaluate and compare the outcomes from the investigator's decisions on multiple treatments of benign or malignant pancreatic diseases.There is a need to understand and improve the current diagnosis and treatment algorithm for pancreatic pathologies. Continued evaluation and study is imperative to ensure that national guidelines are improving to enhance patient cure and/or recovery. All past patients who were treated for a particular benign or malignant pancreatic disease process under evaluation from 2005 to present will be included in this study.

Official Title
-----------------
Evaluation of Outcomes From Treatment of Benign or Malignant Pancreatic Diseases

Conditions
-----------------
Benign or Malignant Pancreatic Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: • All patients diagnosed and treated for pancreatic diseases, benign or malignant from 2005 to present Age ≥18 years Exclusion Criteria: • Patients that are not diagnosed with or treated for pancreatic diseases Age < 18 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival | Number of patients who have been diagnosed with benign or malignant pancreatic disease | 2005 to 2019 |
Protective Ventilation Strategy

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to find a proper ventilation strategy for one-lung ventilation to prevent postoperative pulmonary complications

Official Title
-----------------
Protective Ventilation Strategy During One-lung Ventilation: Effect on Postoperative Pulmonary Complications

Conditions
-----------------
One-lung Ventilation

Intervention / Treatment
-----------------
* Other: ventilator setting during one-lung ventilation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients undergoing elective thoracic surgery ASA I, II, III scheduled > 2 hours of surgery Exclusion Criteria: denied patients age under 18 years FEV1/FVC or FEV1<70% in preoperative pulmonary function test

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: conventional tidal group<br>provide tidal volume of 6ml/kg (predicted body weight) with positive end expiratory pressure of 5cmH2O during one-lung ventilation | Other: ventilator setting during one-lung ventilation<br>* providing various tidal volumes according to the groups with constant PEEP<br>|
| Experimental: low tidal group<br>provide tidal volume of 4ml/kg (predicted body weight) with positive end expiratory pressure of 5cmH2O during one-lung ventilation | Other: ventilator setting during one-lung ventilation<br>* providing various tidal volumes according to the groups with constant PEEP<br>|
| Experimental: high tidal group<br>provide tidal volume of 8ml/kg (predicted body weight) with positive end expiratory pressure of 5cmH2O during one-lung ventilation | Other: ventilator setting during one-lung ventilation<br>* providing various tidal volumes according to the groups with constant PEEP<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| postoperative pulmonary complications | PaO2/FiO2 and/or newly appeared atelectasis, lung infiltration | immediately after operation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
protective ventilation strategy